Hari K Narayan1, Brian Finkelman1, Benjamin French1, Theodore Plappert1, David Hyman1, Amanda M Smith1, Kenneth B Margulies1, Bonnie Ky2. 1. From Department of Pediatrics, Division of Cardiology, The Children's Hospital of Philadelphia, PA (H.K.N.); Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (B. Finkelman, B. French, B.K.); and Department of Medicine, Division of Cardiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (B. Finkelman, T.P., D.H., A.M.S., K.B.M., B.K.). 2. From Department of Pediatrics, Division of Cardiology, The Children's Hospital of Philadelphia, PA (H.K.N.); Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (B. Finkelman, B. French, B.K.); and Department of Medicine, Division of Cardiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (B. Finkelman, T.P., D.H., A.M.S., K.B.M., B.K.). bonnie.ky@uphs.upenn.edu.
Abstract
BACKGROUND: Cardiovascular disease in patients with breast cancer is of growing concern. The longitudinal effects of commonly used therapies, including doxorubicin and trastuzumab, on cardiac remodeling and function remain unknown in this population. We aimed to define the changes in echocardiographic parameters of structure, function, and ventricular-arterial coupling, and their associations with left ventricular ejection fraction (LVEF) and heart failure symptoms. METHODS: In a longitudinal prospective cohort study of 277 breast cancer participants receiving doxorubicin (Dox), trastuzumab (Tras), or both (Dox+Tras), we obtained 1249 echocardiograms over a median follow-up of 2.0 (interquartile range, 1.0-3.0) years. Left ventricular structure, diastolic and contractile function, and ventricular-arterial coupling measures were quantified in a core laboratory blinded to participant characteristics. We evaluated changes in echocardiographic parameters over time, and used repeated-measures regression models to define their association with LVEF decline and recovery. Linear regression models defined the association between early changes in these parameters and subsequent changes in LVEF and heart failure symptoms. RESULTS: Overall, 177 (64%) received Dox, 51 (18%) received Tras, and 49 (18%) received Dox+Tras. With Dox, there was a sustained, modest decrease in LVEF over the follow-up duration (1-year change in LVEF -3.6%; 95% confidence interval [CI], -4.4% to -2.8%; 3-year change -3.8%; 95% CI, -5.1% to -2.5%). With Tras, a similar LVEF decline was observed at 1 year (-4.5%; 95% CI, -6.0% to -2.9%) and 3 years (-2.8%; 95%CI, -5.3 to -0.4%). Participants receiving Dox+Tras demonstrated the greatest declines at 1 year (-6.6%; 95% CI, -8.2 to -5.0%), with partial recovery at 3 years (-2.8%; 95% CI, -4.8 to -0.8%). LVEF declines and recovery were associated primarily with changes in systolic volumes, longitudinal and circumferential strain, and ventricular-arterial coupling indices, effective arterial elastance (Ea) and the coupling ratio Ea/Eessb, without evidence for effect modification across therapies. Early changes in volumes, strain, and Ea/Eessb at 4 to 6 months were associated with 1- and 2-year LVEF changes. Similarly, early changes in strain and Ea were associated with worsening heart failure symptoms at 1 year. CONCLUSIONS: Doxorubicin and trastuzumab resulted in modest, persistent declines in LVEF at 3 years. Changes in volumes, strain, and ventricular-arterial coupling were consistently associated with concurrent and subsequent LVEF declines and recovery across therapies.
BACKGROUND:Cardiovascular disease in patients with breast cancer is of growing concern. The longitudinal effects of commonly used therapies, including doxorubicin and trastuzumab, on cardiac remodeling and function remain unknown in this population. We aimed to define the changes in echocardiographic parameters of structure, function, and ventricular-arterial coupling, and their associations with left ventricular ejection fraction (LVEF) and heart failure symptoms. METHODS: In a longitudinal prospective cohort study of 277 breast cancerparticipants receiving doxorubicin (Dox), trastuzumab (Tras), or both (Dox+Tras), we obtained 1249 echocardiograms over a median follow-up of 2.0 (interquartile range, 1.0-3.0) years. Left ventricular structure, diastolic and contractile function, and ventricular-arterial coupling measures were quantified in a core laboratory blinded to participant characteristics. We evaluated changes in echocardiographic parameters over time, and used repeated-measures regression models to define their association with LVEF decline and recovery. Linear regression models defined the association between early changes in these parameters and subsequent changes in LVEF and heart failure symptoms. RESULTS: Overall, 177 (64%) received Dox, 51 (18%) received Tras, and 49 (18%) received Dox+Tras. With Dox, there was a sustained, modest decrease in LVEF over the follow-up duration (1-year change in LVEF -3.6%; 95% confidence interval [CI], -4.4% to -2.8%; 3-year change -3.8%; 95% CI, -5.1% to -2.5%). With Tras, a similar LVEF decline was observed at 1 year (-4.5%; 95% CI, -6.0% to -2.9%) and 3 years (-2.8%; 95%CI, -5.3 to -0.4%). Participants receiving Dox+Tras demonstrated the greatest declines at 1 year (-6.6%; 95% CI, -8.2 to -5.0%), with partial recovery at 3 years (-2.8%; 95% CI, -4.8 to -0.8%). LVEF declines and recovery were associated primarily with changes in systolic volumes, longitudinal and circumferential strain, and ventricular-arterial coupling indices, effective arterial elastance (Ea) and the coupling ratio Ea/Eessb, without evidence for effect modification across therapies. Early changes in volumes, strain, and Ea/Eessb at 4 to 6 months were associated with 1- and 2-year LVEF changes. Similarly, early changes in strain and Ea were associated with worsening heart failure symptoms at 1 year. CONCLUSIONS:Doxorubicin and trastuzumab resulted in modest, persistent declines in LVEF at 3 years. Changes in volumes, strain, and ventricular-arterial coupling were consistently associated with concurrent and subsequent LVEF declines and recovery across therapies.
Authors: Jens-Uwe Voigt; Gianni Pedrizzetti; Peter Lysyansky; Tom H Marwick; Hélène Houle; Rolf Baumann; Stefano Pedri; Yasuhiro Ito; Yasuhiko Abe; Stephen Metz; Joo Hyun Song; Jamie Hamilton; Partho P Sengupta; Theodore J Kolias; Jan d'Hooge; Gerard P Aurigemma; James D Thomas; Luigi Paolo Badano Journal: J Am Soc Echocardiogr Date: 2015-02 Impact factor: 5.251
Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: G de Simone; R B Devereux; M J Roman; A Ganau; P S Saba; M H Alderman; J H Laragh Journal: J Am Coll Cardiol Date: 1994-05 Impact factor: 24.094
Authors: Tomas G Neilan; Otavio R Coelho-Filho; Diego Pena-Herrera; Ravi V Shah; Michael Jerosch-Herold; Sanjeev A Francis; Javid Moslehi; Raymond Y Kwong Journal: Am J Cardiol Date: 2012-08-21 Impact factor: 2.778
Authors: Kan N Hor; Janaka Wansapura; Larry W Markham; Wojciech Mazur; Linda H Cripe; Robert Fleck; D Woodrow Benson; William M Gottliebson Journal: J Am Coll Cardiol Date: 2009-04-07 Impact factor: 24.094
Authors: Jenica N Upshaw; Robin Ruthazer; Kathy D Miller; Susan K Parsons; John K Erban; Anne M O'Neill; Biniyam Demissei; George Sledge; Lynne Wagner; Bonnie Ky; David M Kent Journal: Clin Breast Cancer Date: 2019-05-02 Impact factor: 3.225
Authors: Biniyam G Demissei; Brian S Finkelman; Rebecca A Hubbard; Liyong Zhang; Amanda M Smith; Karyn Sheline; Caitlin McDonald; Hari K Narayan; Vivek Narayan; Adam J Waxman; Susan M Domchek; Angela DeMichele; Payal Shah; Amy S Clark; Angela R Bradbury; Joseph R Carver; Jenica Upshaw; Saro H Armenian; Peter Liu; Bonnie Ky Journal: Cancer Date: 2019-05-01 Impact factor: 6.860
Authors: Srilakshmi Vallabhaneni; Kathleen W Zhang; Jose A Alvarez-Cardona; Joshua D Mitchell; Henning Steen; Pamela K Woodard; Daniel J Lenihan Journal: Int J Cardiovasc Imaging Date: 2021-05-12 Impact factor: 2.357
Authors: Lisa D Levine; Jennifer Lewey; Nathanael Koelper; Katheryne L Downes; Zolt Arany; Michal A Elovitz; Mary D Sammel; Bonnie Ky Journal: Pregnancy Hypertens Date: 2019-05-30 Impact factor: 2.899
Authors: Kathleen W Zhang; Brian S Finkelman; Gaurav Gulati; Hari K Narayan; Jenica Upshaw; Vivek Narayan; Ted Plappert; Virginia Englefield; Amanda M Smith; Carina Zhang; W Gregory Hundley; Bonnie Ky Journal: JACC Cardiovasc Imaging Date: 2018-03-14
Authors: Dylan J Richards; Yang Li; Charles M Kerr; Jenny Yao; Gyda C Beeson; Robert C Coyle; Xun Chen; Jia Jia; Brooke Damon; Robert Wilson; E Starr Hazard; Gary Hardiman; Donald R Menick; Craig C Beeson; Hai Yao; Tong Ye; Ying Mei Journal: Nat Biomed Eng Date: 2020-04-13 Impact factor: 25.671